These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19432790)

  • 1. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
    Ahmed I; Dalmasso C; Haramburu F; Thiessard F; Broët P; Tubert-Bitter P
    Biometrics; 2010 Mar; 66(1):301-9. PubMed ID: 19432790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
    Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonparametric bayesian estimation of positive false discovery rates.
    Tang Y; Ghosal S; Roy A
    Biometrics; 2007 Dec; 63(4):1126-34. PubMed ID: 17501943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Haramburu F; Kreft-Jais C; Bégaud B; Tubert-Bitter P
    Drug Saf; 2012 Jun; 35(6):495-506. PubMed ID: 22612853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A knowledge based approach for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Stud Health Technol Inform; 2004; 107(Pt 1):626-30. PubMed ID: 15360888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.
    van Puijenbroek EP; Bate A; Leufkens HG; Lindquist M; Orre R; Egberts AC
    Pharmacoepidemiol Drug Saf; 2002; 11(1):3-10. PubMed ID: 11998548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust estimation of the false discovery rate.
    Pounds S; Cheng C
    Bioinformatics; 2006 Aug; 22(16):1979-87. PubMed ID: 16777905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach.
    Bousquet C; Henegar C; Louët AL; Degoulet P; Jaulent MC
    Int J Med Inform; 2005 Aug; 74(7-8):563-71. PubMed ID: 15955732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining unexpected temporal associations: applications in detecting adverse drug reactions.
    Jin HW; Chen J; He H; Williams GJ; Kelman C; O'Keefe CM
    IEEE Trans Inf Technol Biomed; 2008 Jul; 12(4):488-500. PubMed ID: 18632329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative signal detection using spontaneous ADR reporting.
    Bate A; Evans SJ
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):427-36. PubMed ID: 19358225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision strategies that maximize the area under the LROC curve.
    Khurd P; Gindi G
    IEEE Trans Med Imaging; 2005 Dec; 24(12):1626-36. PubMed ID: 16353373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of data mining in pharmacovigilance.
    Hauben M; Madigan D; Gerrits CM; Walsh L; Van Puijenbroek EP
    Expert Opin Drug Saf; 2005 Sep; 4(5):929-48. PubMed ID: 16111454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A shrinkage-based comparative assessment of observed-to-expected disproportionality measures.
    Gipson G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):589-96. PubMed ID: 22290739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.